AstraZeneca has been developing cancer medicines for more than 40 years. Many of these have increased survival rates for patients in the UK and around the world. Even as R&D continues to push boundaries in how we understand and fight cancer, there is still more to do.
We are at the heart of oncology R&D in the UK and are committed to advancing the science of oncology to deliver life-changing medicines. Our ambition is to eliminate cancer as a cause of death through scientific discovery and collaborations and ensure that these reach people in most need.
Faslodex (fulvestrant) is indicated:
• as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:
- not previously treated with endocrine therapy, or
- with disease relapse on or after adjuvant antioestrogen therapy, or disease progression on antioestrogen therapy.
• in combination with palbociclib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy (see section 5.1).
In pre- or perimenopausal women, the combination treatment with palbociclib should be combined with a luteinising hormone releasing hormone (LHRH) agonist.
Iressa (gefitinib) is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK.
Lynparza▼ (olaparib) is monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy.
TAGRISSO▼ (osimertinib) is indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung cancer (NSCLC).
Zoladex® (goserelin) is a Luteinising Hormone-Releasing Hormone analogue (LHRHa). Zoladex® is available as a 3.6 mg implant and a 10.8 mg implant in a pre-filled syringe.
GB-9784 - November 2017